

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/509,237	03/20/2000	Seth D. Rose	344-P-16-USA	9691
7590 04/19/2006			EXAMINER	
Indiano Vaughan LLP			FUBARA, BLESSING M	
One North Penn				
Suite 850			ART UNIT	PAPER NUMBER
Indianapolis, IN 46204			1618	
			DATE MAILED: 04/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/509,237	ROSE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Blessing M. Fubara	1618				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the	ne correspondence address				
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory perion - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply be reply within the statutory minimum of thirty (30) and will apply and will expire SIX (6) MONTHS tute, cause the application to become ABAND	be timely filed I days will be considered timely. I drow the mailing date of this communication. ONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 25	April 2005.					
2a) This action is FINAL . 2b) ⊠ TI	his action is non-final.					
• •	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
 4) ☐ Claim(s) 9 is/are pending in the application. 4a) Of the above claim(s) is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 9 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and 						
Application Papers						
9)☐ The specification is objected to by the Exami	ner.					
10)☐ The drawing(s) filed on is/are: a)☐ a	ccepted or b) objected to by the	ne Examiner.				
Applicant may not request that any objection to the	ne drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the		•				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a life.	ents have been received. ents have been received in Applic riority documents have been rece eau (PCT Rule 17.2(a)).	cation No eived in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summ					
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	Paper No(s)/Ma 5) Notice of Inform 6) Other:	il Date nal Patent Application (PTO-152)				

Application/Control Number: 09/509,237 Page 2

Art Unit: 1618

DETAILED ACTION

Examiner acknowledges receipt of change of power of attorney, amendment and remarks filed 1/12/06. Claim 9 is pending.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

2. Claim 9 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The issue raised in the previous office has been addressed. However, it is unclear if the "modifying the water solubility of the polymer ... by attaching the hydrophobic group of the compound containing the hydrophobic group to the water soluble polymer to produce a water insoluble interaction product" is a step and not part of the liquid composition.

The above phrase is interpreted as a method step for purposes of examining the claim.

Clarification is respectfully requested.

It is also not immediately clear what the compound containing the hydrophobic group may be from the specification that applicants consider as their invention. If a particular disclosure of that compound is present in the as filed specification, then, a recitation of the compound or the compounds in a Markush group, if more than 1 may help to expedite the prosecution of the claimed invention.

Furthermore, a search for polyiminodiacetamide returned zero hit. Clarification is respectfully requested to determine if this is a new compound or it is a misspelled word.

Application/Control Number: 09/509,237 Page 3

Art Unit: 1618

Claim Rejections - 35 USC § 103

3. The rejection of claim 9 under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Katada et al. (US 5,080,889) is withdrawn because the step where the water soluble polymer and the compound containing the hydrophobic group are interacted to modify the water soluble polymer is not disclosed in the Katada prior art. Since that phrase is taken as part of a positive method step of the claims, then applicants' argument is persuasive.

- 4. The rejection of claim 9 under 35 U.S.C. 103(a) as being unpatentable over Mueller et al. (US 4,826,677) is withdrawn because the step where the water soluble polymer and the compound containing the hydrophobic group are interacted to modify the water soluble polymer is not disclosed in the Mueller prior art. Since that phrase is taken as part of a positive method step of the claims, then applicants' argument is persuasive.
- 5. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over applicants' admitted prior art in view of Alwattari et al. (US5,874,072) or Rechelbacher et al. (US 5,849,280).

Applicants in the specification at page 8, lines 8-19, admit of a composition comprising hydrophobe modified hydroxypropyl cellulose water soluble polymer, ethanol that polymerizes in-situ upon application to body tissue.

However, the claim requires either carboxymethylcellulose or hydroxyethylcellulose.

Alwattari discloses that hydroxypropylcellulose and hydroxyethylcellulose are equivalent as film forming polymers (column 3, lines 56-63); similarly, Rechelbacher discloses that hydroxypropylcellulose and hydroxyethylcellulose are equivalent as film forming polymers

Art Unit: 1618

(claim 37). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use hydroxypropylcellulose modified by a compound containing hydrophobic group as the film-forming polymer. It would have been obvious to substitute the hydroxyethylcellulose polymer of Alwattari or Rechelbacher for the hydroxypropylcellulose in view of the fact that Alwattari or Rechelbacher teach hydroxypropylcellulose and hydroxyethylcellulose as equivalent film forming polymers and with the expectation that the composition will form a film upon application of the composition to a body tissue.

6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pomerantz (US 5,081,158) in view of Alwattari et al. (US5,874,072) or Rechelbacher et al. (US 5,849,280).

Pomerantz discloses applies a composition comprising modified hydroxypropylcellulose, topical anesthetics, ethanol to body tissue and the composition forms a film on the body tissue (abstract; columns 1-4; Example 1-4 and claims 1-5).

However, the claim requires either carboxymethylcellulose or hydroxyethylcellulose. Alwattari discloses that hydroxypropylcellulose and hydroxyethylcellulose are equivalent as film forming polymers (column 3, lines 56-63); similarly, Rechelbacher discloses that hydroxypropylcellulose and hydroxyethylcellulose are equivalent as film forming polymers (claim 37). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use hydroxypropylcellulose modified by a compound containing hydrophobic group as the film-forming polymer. It would have been obvious to substitute the hydroxyethylcellulose polymer of Alwattari or Rechelbacher for the hydroxypropylcellulose of Pomerantz in view of the fact that Alwattari and Rechelbacher teach hydroxypropylcellulose and

Application/Control Number: 09/509,237 Page 5

Art Unit: 1618

hydroxyethylcellulose as equivalent film forming polymers and with the expectation that the composition will form a film upon application of the composition to a body tissue.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Blessing Fubara Affilia Mara Patent Examiner

Tech. Center 1600